Type(s) of biological/targeted therapy-Daratumumab Posts on Medivizor
Navigation Menu

Type(s) of biological/targeted therapy-Daratumumab Posts on Medivizor

Significance of health related quality of life to confirm the benefits of D-VMP therapy in patients with newly diagnosed multiple myeloma

Significance of health related quality of life to confirm the benefits of D-VMP therapy in patients with newly diagnosed multiple myeloma

Posted by on Aug 7, 2021 in Multiple Myeloma | 0 comments

In a nutshell The study reports the outcomes of cancer treatment on the health-related quality of life (HRQoL) in patients with newly diagnosed multiple myeloma (MM) who were not eligible for a stem cell transplant (SCT). This study showed that treatment with VMP (bortezomib, melphalan, and prednisone) with or without daratumumab (Darzalex) improved...

Read More

Are injections under the skin of daratumumab as effective as intravenous infusions for patients with relapsed or refractory multiple myeloma?

Are injections under the skin of daratumumab as effective as intravenous infusions for patients with relapsed or refractory multiple myeloma?

Posted by on Jun 13, 2020 in Multiple Myeloma | 0 comments

In a nutshell This study examined if subcutaneous (sc) injections of daratumumab (Darzalex) were as effective and safe as intravenous (iv) infusions for patients with relapsed or refractory multiple myeloma (MM). The authors found that sc injections were as effective as iv infusions and caused fewer side effects. Some background Daratumumab...

Read More

Myeloma Update From ASCO 2017

Myeloma Update From ASCO 2017

Posted by on Oct 7, 2017 in Multiple Myeloma | 0 comments

Video information: On location at the recent 2017 American Society of Clinical Oncology meeting (ASCO), Dr. Hearn Jay Cho of Mount Sinai Hospital discusses news out of ASCO 2017 and what it means for myeloma patients and care partners. Dr. Cho highlights news out of the meeting, including how experts are manipulating the immune system, precision...

Read More
ABOUT USHOW IT WORKSBLOG NEWS PARTNERS CONTACT US PRIVACY POLICY TERMS OF USE
FROM OUR BLOG
LATEST NEWS
CONNECT WITH US
© 2024 Medivizor